FIELD: chemistry； pharmaceutics.SUBSTANCE: invention relates to a tetrahydropyridine compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, use thereof, a pharmaceutical composition based thereon and a method of treating bacterial infections caused by gram-negative bacteria. In general formula I n is equal to 1 or 2； R1 is C1-C6 alkyl； R2 is C1-C6 alkyl； R3 denotes hydrogen； L is phenyl, pyridinyl or absent, where at least one H of phenyl or pyridinyl can be substituted with halogen, C1-C6 alkyl or C1-C6 haloalkyl； D is C≡C or absent； E is C≡C or absent； G is C1-C6 alkyl, C3-C7 cycloalkyl, 4–6-member heterocycloalkyl with one N atom, phenyl, pyridinyl, furanyl, thiophenyl or imidazolyl, where at least one H C1-C6 alkyl can be substituted with halogen, -NRARB, -OH or -ORC, at least one H 4–6-membered heterocycloalkyl with one N atom can be substituted with C1-C6 alkyl, -(C═O)-C1-C6 alkyl or -S(=O)2-C1-C6 alkyl, at least one H-phenyl, pyridinyl, furanyl, thiophenyl or imidazolyl can be substituted with C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkyl-NRARB, halogen, nitro, cyano, -NRARB, -OH, -ORC, -S(=O)2-C1-C6 alkyl or -S(=O)2-NRARB； RA and RB, each independently represent hydrogen or C1-C6 alkyl, or RA and RB can be bonded together to form 4–6-member ring, where 4–6-member ring can have an O atom, and at least one H 4–6-member ring can be substituted with C1-C6 hydroxyalkyl； RC is C1-C6 alkyl, C1-C6 hydroxyalkyl, -(C=O)-NRDRE or -S(=O)2-C1-C6 alkyl； and RD and RE, each independently represent hydrogen. Invention also relates to a novel tetrahydropyridine derivative, stereoisomer or pharmaceutically acceptable salt thereof, methods of producing compounds, methods of inhibiting UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC), methods of treating infections caused by gram-negative bacteria, use of compounds for preparing therapeutic drugs for treating infections caused by gram-negative bacteria, and pharmaceutical compos
